Friday, 16 October 2026European Markets

CLARANOVA Stock Was Up By 15.88% Today

Loading stream...

(vianews) - the market ended the session with claranova (cla.pa) jumping 15.88% to €2.96 on monday while cac 40 rose 0.55% to €7,689.80.

claranova's last close was €2.55, 3.41% under its 52-week high of €2.64.

about claranova

claranova se, a technology company, engages in personalized e-commerce, software publishing, and internet of things (iot) management in france, the united states, the united kingdom, germany, other european countries, and internationally. it operates in three segments: planetart, avanquest, and mydevices. the planetart segment offers photos, frames, personalized books, and freeprints mobile applications. the avanquest segment provides antivirus, ad blocker, cleaning, and optimization tools under the adaware brand; document management tools under the sodapdf brand; and photo editor software and applications developed under the inpixio brand. the mydevices segment offers iot solutions. claranova se was incorporated in 1984 and is headquartered in courbevoie, france.

earnings per share

as for profitability, claranova has a trailing twelve months eps of €-0.23.

revenue growth

year-on-year quarterly revenue growth declined by 0.8%, now sitting on 507m for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, claranova's stock is considered to be oversold (<=20).

more news about claranova (cla.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com